PriceTargets.com logo

Mangoceuticals - MGRX Stock Price Target and Predictions

  • Consensus Rating: Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 1
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.18 As of 12/4/2025 05:00 PM ET
▼ -0.05 (-4.07%)

This chart shows the closing price for MGRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Mangoceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGRX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Mangoceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.18.

This chart shows the closing price for MGRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Sell

The current consensus among 1 contributing investment analysts is to sell stock in Mangoceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/6/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/5/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
12/5/2025

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/1/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/24/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/17/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/11/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/5/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
9/27/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
(Data available from 12/5/2020 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/8/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/7/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/6/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/6/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/5/2025
  • 2 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
12/5/2025

Current Sentiment

  • 2 very positive mentions
  • 4 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Mangoceuticals logo
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Read More

Today's Range

Now: $1.18
Low: $1.15
High: $1.24

50 Day Range

MA: $1.88
Low: $1.00
High: $2.74

52 Week Range

Now: $1.18
Low: $0.98
High: $6.15

Volume

154,854 shs

Average Volume

3,956,957 shs

Market Capitalization

$16.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Mangoceuticals?

The following sell-side analysts have issued research reports on Mangoceuticals in the last twelve months: Wall Street Zen, and Weiss Ratings.
View the latest analyst ratings for MGRX.

What is the current price target for Mangoceuticals?

0 Wall Street analysts have set twelve-month price targets for Mangoceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Mangoceuticals in the next year.
View the latest price targets for MGRX.

What is the current consensus analyst rating for Mangoceuticals?

Mangoceuticals currently has 1 sell rating from Wall Street analysts. The stock has a consensus analyst rating of "Sell." A "sell" rating indicates that analysts believe MGRX will underperform the market and that investors should sell shares of Mangoceuticals.
View the latest ratings for MGRX.

What other companies compete with Mangoceuticals?

Other companies that are similar to Mangoceuticals include Biodesix, Agape ATP, P3 Health Partners, Basel Medical Group and Marpai. Learn More about companies similar to Mangoceuticals.

How do I contact Mangoceuticals' investor relations team?

The company's listed phone number is 833-626-4679 and its investor relations email address is [email protected]. The official website for Mangoceuticals is www.mangorx.com. Learn More about contacing Mangoceuticals investor relations.